Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Neoimmunetech Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single pending action is being reviewed by 1 distinct examiner and is located within 1 distinct art unit. Such a concentrated profile indicates that the company's current prosecution activity is focused on a specific technical matter handled by a single administrative group at the patent office.
The busiest examiner for this portfolio is PATTERSON, SARAH COOPER, who is assigned 1 busiest examiner pending office action. Because the total number of pending office actions for the company is 1, this examiner is responsible for the entire current workload. For practitioners, this means that the prosecution strategy for Neoimmunetech Inc. is presently dependent on the specific examination style and technical interpretations of PATTERSON, SARAH COOPER. The lack of other distinct examiners or art units in the current data suggests a singular focus for the company's pending intellectual property matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 1 | 55.3% | +59.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17792663 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND A BISPECIFIC ANTIBODY | PATTERSON, SARAH COOPER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17792663 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND A BISPECIFIC ANTIBODY | PATTERSON, SARAH COOPER | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17792663 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND A BISPECIFIC ANTIBODY | PATTERSON, SARAH COOPER | 1675 | §103§112 | Final Rejection | — | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial